Mesothelioma Matters UK highlighted RS Oncology in their Autumn Newsletter.
15% of cancer patients develop pleural effusion as their disease spreads to the lungs and accumulates excess fluid. This condition is common among mesothelioma patients. Earlier this year, RS Oncology, LLC, a US-based biotechnical company focused on the treatment of patients with malignant pleural effusion (MPE) and mesothelioma, initiated its MITOPE clinical trial, a first-in-human Phase 1/2 clinical trial in the UK.